Navigation Links
Freeslate’s Biologics Formulation System Selected by Sanofi Pasteur to Improve Efficiency of Formulation Development
Date:8/21/2013

Sunnyvale, Calif. (PRWEB) August 21, 2013

Freeslate, Inc., the leading provider of high throughput research solutions, today announced that Sanofi Pasteur, the vaccines division of Sanofi, has purchased Freeslate’s Biologics Formulation System, a comprehensive solution for accelerating research in vaccine and protein formulation development. The system automates sample preparation, sample stressing, and formulation analysis, allowing for the development of stable, robust formulations significantly faster with reduced API consumption.

Based on the Freeslate Core Module 3 (CM3) automation platform, the Biologics Formulation System combines liquid dispense and controlled heating/cooling/mixing with new automated measurements of pH, viscosity, and particle counting. Integrated by Freeslate’s Lab Execution and Analysis (LEA) software suite, the system provides intuitive experiment design and allows for the control and data integration of a range of third party analytics including Dynamic Light Scatter (DLS), UV/VIS plate readers, and High Pressure Liquid Chromatography (HPLC), maximizing R&D productivity.

“We are excited to be selected by a global leader in vaccines and are pleased they recognize the value our tools bring to the advancement of formulation development,” said John S. Senaldi, President and CEO of Freeslate. “As demonstrated by the adoption of our systems in Europe and across the globe, combinatorial approaches to vaccine formulation development can significantly accelerate productivity.”

Freeslate has built strong capabilities around automated solutions addressing the complex problems of drug development. The company’s products enable customers to better manage capacity by performing and assessing formulations, minimize later stage reformulations by exploring a broader analytical space early in development, and
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. BiologicsMD, Inc. Announces Issuance of First U.S. Patent for PTH-CBD™
2. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
3. Synthetic Biologics to Report Second Quarter 2013 Financial Results
4. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
5. Synthetic Biologics to Present at OneMedForum New York 2013
6. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
7. Predictive Biomarker Discovery for Oncology Small-Molecules and Biologics - a Webinar Hosted by Xtalks
8. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
9. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
10. As the life science industry evolves, it is clear that biologics are here to stay!
11. Seminar Spotlights Key Trends in Biologics and Biosimilars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
(Date:12/17/2014)... 17, 2014 Achim Noack has been ... Stoller Group. In this position, Noack will assist Jerry ... matters, develop marketing strategy and supervise global marketing management ... “Achim has tremendous knowledge and experience in the crop ... “His experience and innovative thinking will be a great ...
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
(Date:12/17/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... as changes to Martine Rothblatt , Ph.D,s compensation ... United Therapeutics announced the promotion of Roger ... and David Zaccardelli , Pharm.D. to Executive Vice ... promotions, Dr. Rothblatt,s title will change from Chairman and ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... OLDSMAR, Fla., July 10 Cryo-Cell,International, Inc. (OTC ... largest and most established family cord blood banks, ... months ended May 31, 2008., Consolidated revenues ... relatively flat, as compared to approximately $4.5,million for ...
... Today,s Pharmaceutical Research,and Manufacturers of America ... practice,of providing non-educational materials to physicians ... of the physician/industry representative interaction,says Jim ... leading non-profit,organization dedicated to educating and ...
... Robust ... Pipeline -, ... and MacroChem Corporation (OTC Bulletin Board:,MACM) announced today that they had ... the issuance of 2.5,million shares of Access Pharmaceuticals, common stock. MacroChem,s ...
Cached Biology Technology:Cryo-Cell International, Inc. Reports Second Quarter 2008 Results 2Cryo-Cell International, Inc. Reports Second Quarter 2008 Results 3Cryo-Cell International, Inc. Reports Second Quarter 2008 Results 4Cryo-Cell International, Inc. Reports Second Quarter 2008 Results 5Cryo-Cell International, Inc. Reports Second Quarter 2008 Results 6CMR Institute: Education Key to Physician/Representative Relationship 2Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp. 2Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp. 3Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp. 4
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE ... collaboration catalyst that provides the connective tissue that enhances ... enabling them to easily share client-level information; earned a ... to expand to organizations serving seniors aging in community ... Diego" partner on December 11 th 4-6p. ...
(Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
(Date:12/3/2014)... IRVINE, Calif. , Dec. 2, 2014 /PRNewswire/ ... of globally deployed, innovative test solutions for military, ... the newest version of its successful TS-900 ... the performance and features of high-end systems to ... with outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... has pieced together how the hominid Australopithecus sediba ... million years ago. Their research, which appears in six papers ... also shows that Au. sediba had a notable ... and more flexible lower back. Together, the studies offer ...
... purposely set to burn crop residues and get the ... evidenced in this image from the MODIS instrument on ... these types of fires can be found at this ... was collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) ...
... new treatment for alcoholism called nalmefene is effective and ... says a new study published this week in ... as the primary treatment goal for alcohol dependence, and ... relapse prevention. However, relapse rates remain high and a ...
Cached Biology News:New research reveals how human ancestor walked, chewed, and moved 2New research reveals how human ancestor walked, chewed, and moved 3A new treatment option for alcohol dependence: Reduced consumption rather than abstinence 2
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Direct ELISA Assay Diluent, 10 L...
SpectroQuest single beam 1.8nm UV/Vis spectrophotometer; stand-alone unit...
Biology Products: